Optellum, Ai Lung Cancer Diagnosis Innovator, Secures $14M Series A Funding To Accelerate Expansion
Sep 27, 2022•almost 3 years ago
Amount Raised
$14 Million
Round Type
series a
Description
Optellum, an Oxford-based medtech company that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round. The investment will enable Optellum to scale its base, operations, and commercial launches in the UK and USA; accelerate research and development; and expand its platform into personalized therapy decisions by integrating imaging data with molecular data, robotics, and liquid biopsies.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech